Treatment With Neuraminidase Inhibitors for Critically Ill Patients With Influenza A (H1N1)pdm09 | Zendy

Janice K. Louie | Zendy; Samuel Yang | Zendy; M Yessenia Acosta | Zendy; C. Yen | Zendy; M Samuel | Zendy; R. S. Schechter | Zendy; Hugo Guevara | Zendy; Tim Uyeki | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Treatment With Neuraminidase Inhibitors for Critically Ill Patients With Influenza A (H1N1)pdm09

Author(s) -

Janice K. Louie,

Samuel Yang,

M Yessenia Acosta,

C. Yen,

M Samuel,

R. S. Schechter,

Hugo Guevara,

Tim Uyeki

Publication year - 2012

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/cis636

Subject(s) - neuraminidase , medicine , critically ill , neuraminidase inhibitor , intensive care medicine , oseltamivir , zanamivir , critical illness , virology , covid-19 , virus , disease , infectious disease (medical specialty)

Neuraminidase inhibitor (NAI) antiviral drugs can shorten the duration of uncomplicated influenza when administered early (<48 hours after illness onset) to otherwise healthy outpatients, but the optimal timing of effective therapy for critically ill patients is not well established.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research